• Je něco špatně v tomto záznamu ?

Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection

JC. Arce, AN. Andersen, M. Fernández-Sánchez, H. Visnova, E. Bosch, JA. García-Velasco, P. Barri, P. de Sutter, BM. Klein, BC. Fauser,

. 2014 ; 102 (6) : 1633-40.e5.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15014053

OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations. DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial. SETTING: Seven infertility centers in four countries. PATIENT(S): Two hundred sixty-five women aged ≤37 years. INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle. MAIN OUTCOME MEASURE(S): Number of oocytes retrieved. RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum. CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level. CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15014053
003      
CZ-PrNML
005      
20150427102935.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.fertnstert.2014.08.013 $2 doi
035    __
$a (PubMed)25256937
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Arce, Joan-Carles $u Reproductive Health, Ferring Pharmaceuticals, Copenhagen, Denmark. Electronic address: jca@ferring.com. $7 gn_A_00008124
245    10
$a Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimüllerian hormone-stratified, dose-response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection / $c JC. Arce, AN. Andersen, M. Fernández-Sánchez, H. Visnova, E. Bosch, JA. García-Velasco, P. Barri, P. de Sutter, BM. Klein, BC. Fauser,
520    9_
$a OBJECTIVE: To evaluate the dose-response relationship of a novel recombinant human FSH (rhFSH; FE 999049) with respect to ovarian response in patients undergoing IVF/intracytoplasmic sperm injection treatment; and prospectively study the influence of initial antimüllerian hormone (AMH) concentrations. DESIGN: Randomized, controlled, assessor-blinded, AMH-stratified (low: 5.0-14.9 pmol/L [0.7-<2.1 ng/mL]; high: 15.0-44.9 pmol/L [2.1-6.3 ng/mL]) trial. SETTING: Seven infertility centers in four countries. PATIENT(S): Two hundred sixty-five women aged ≤37 years. INTERVENTION(S): Controlled ovarian stimulation with either 5.2, 6.9, 8.6, 10.3, or 12.1 μg of rhFSH, or 11 μg (150 IU) of follitropin alfa in a GnRH antagonist cycle. MAIN OUTCOME MEASURE(S): Number of oocytes retrieved. RESULT(S): The number of oocytes retrieved increased in an rhFSH dose-dependent manner, from 5.2 ± 3.3 oocytes with 5.2 μg/d to 12.2 ± 5.9 with 12.1 μg/d. The slopes of the rhFSH dose-response curves differed significantly between the two AMH strata, demonstrating that a 10% increase in dose resulted in 0.5 (95% confidence interval 0.2-0.7) and 1.0 (95% confidence interval 0.7-1.3) more oocytes in the low and high AMH stratum, respectively. Fertilization rate and blastocyst/oocyte ratio decreased significantly with increasing rhFSH doses in both AMH strata. No linear relationship was observed between rhFSH dose and number of blastocysts overall or by AMH strata. Five cases of ovarian hyperstimulation syndrome were reported for the three highest rhFSH doses and in the high AMH stratum. CONCLUSION(S): Increasing rhFSH doses results in a linear increase in number of oocytes retrieved in an AMH-dependent manner. The availability of blastocysts is less influenced by the rhFSH dose and AMH level. CLINICAL TRIAL REGISTRATION NUMBER: NCT01426386.
650    _2
$a dospělí $7 D000328
650    _2
$a antimülleriánský hormon $x aplikace a dávkování $7 D054304
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fertilizace in vitro $x metody $7 D005307
650    _2
$a folikuly stimulující hormon lidský $x aplikace a dávkování $7 D043373
650    _2
$a lidé $7 D006801
650    12
$a odběr oocytu $7 D054315
650    _2
$a indukce ovulace $x metody $7 D010062
650    _2
$a rekombinantní proteiny $x aplikace a dávkování $7 D011994
650    _2
$a intracytoplazmatické injekce spermie $x metody $7 D020554
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Andersen, Anders Nyboe $u Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. $7 gn_A_00006056
700    1_
$a Fernández-Sánchez, Manuel $u IVI Sevilla, Seville, Spain.
700    1_
$a Visnova, Hana $u IVF CUBE SE, Prague, Czech Republic.
700    1_
$a Bosch, Ernesto $u IVI Valencia, Valencia, Spain.
700    1_
$a García-Velasco, Juan Antonio $u IVI Madrid, Madrid, Spain.
700    1_
$a Barri, Pedro $u Obstetrics, Gynecology & Reproduction, IU Dexeus, Barcelona, Spain.
700    1_
$a de Sutter, Petra $u Reproductive Medicine, Universitair Ziekenhuis, Ghent, Belgium.
700    1_
$a Klein, Bjarke M $u Global Biometrics, Ferring Pharmaceuticals, Copenhagen, Denmark.
700    1_
$a Fauser, Bart C J M $u Division Woman & Baby, University Medical Center Utrecht, Utrecht, the Netherlands.
773    0_
$w MED00001795 $t Fertility and sterility $x 1556-5653 $g Roč. 102, č. 6 (2014), s. 1633-40.e5
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25256937 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150427103239 $b ABA008
999    __
$a ok $b bmc $g 1071634 $s 896931
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 102 $c 6 $d 1633-40.e5 $i 1556-5653 $m Fertility and sterility $n Fertil Steril $x MED00001795
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace